Date: 2013-06-26
Type of information: Series B financing round
Company: Complix (Belgium)
Investors: Gimv (Belgium) Edmond de Rothschild Investment Partners (France)
Amount: € 12 million
Funding type: Series B financing round
Planned used:
Others: * On June 26, 2013, Gimv and Gimv managed Biotech Fonds Vlaanderen invest in Complix, a biopharmaceutical company focused on the discovery and development of novel therapeutics based on its Alphabodies™ platform. This investment is part of a total Series B equity financing round of € 12 million from a syndicate of important life sciences investors, co-led by new investors Gimv and Edmond de Rothschild Investment Partners.
Complix is a biopharmaceutical company developing a pipeline of therapeutics, called AlphabodiesTM, mainly focused on oncology and autoimmunity. Alphabodies are a revolutionary class of protein therapeutics that combine the attractive features of antibodies, including high target specificity and affinity, with the benefits from small chemical drugs such as extreme stability and their capacity to penetrate cells. As a result of these unique features, Alphabodies can tackle a broad range of diseases where treatment options today are limited or non-existent. Since its founding in 2008 Complix has raised a total of € 26 million in funding, including this € 12 million capital round. This financing round will be used to develop a first set of therapeutic Alphabodies for treatment of cancer and auto-immune indications, and to further develop and validate the company’s unique Alphabody platform.
Complix is the sixth joint biotech investment in the current portfolio of Gimv and Biotech Fonds Vlaanderen next to Ablynx, Actogenix, Agrosavfe, Multiplicom and Pronota.
Therapeutic area: Cancer - Oncology - Autoimmune diseases
